The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.

The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.